Benefit of Bevacizumab in Glioblastoma Under Discussion

This past year, ABC2 called upon the FDA, Genentech and the NCI’s Radiation Therapy Oncology Group, to harmonize the data generated in the various Avastin trials. 

Coordination between the groups would provide better data for the FDA as it considers final approval for the use of Avastin in treating GBM.  It would also provide better information for patients and physicians regarding the risks and benefits of using Avastin to treat GBM. 

This topic continues to draw a lot of attention in the field. 

Click HERE to read a recent article from Medscape discussing an article released in the February 20 issue of the New England Journal of Medicine on this topic.  ABC2’s petitioning of the FDA is noted.

 

 

 

Share |
July 15, 2015 03:44 PM
Progress continues on the ABC2-funded immunotherapy research by Catherine Flores and her team at UF.
July 14, 2015 03:47 PM
Guest blogger Shawn Peters shares why he's running the 2015 Marine Corps Marathon to support ABC2.
June 17, 2015 09:46 AM
These studies provide a foundational rationale for ABC2's efforts in the profiling space.

Join us in our fight for a cure!

Twitter